קפרה 250 מג ישראל - עברית - Ministry of Health

קפרה 250 מג

cts ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 250 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

קפרה 500 מג ישראל - עברית - Ministry of Health

קפרה 500 מג

cts ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 500 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

קפרה 1000 מג ישראל - עברית - Ministry of Health

קפרה 1000 מג

cts ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 1000 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

קפרה תמיסה לבליעה ישראל - עברית - Ministry of Health

קפרה תמיסה לבליעה

cts ltd - levetiracetam - תמיסה - levetiracetam 100 mg/ml - levetiracetam - levetiracetam - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. keppra is indicated as adjunctive therapy - in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

זרוקסולין ישראל - עברית - Ministry of Health

זרוקסולין

rafa laboratories ltd - metolazone 5 mg - tablets - metolazone - for the treatment of salt and water retention including: edema accompanying congestive heart failure, edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. for hypertension, alone or in combination with other antihypertensive drugs of a different class.

וימפט 50 מג ישראל - עברית - Ministry of Health

וימפט 50 מג

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 50 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

וימפט 100 מג ישראל - עברית - Ministry of Health

וימפט 100 מג

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 100 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

וימפט 150 מג ישראל - עברית - Ministry of Health

וימפט 150 מג

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 150 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

וימפט 200 מג ישראל - עברית - Ministry of Health

וימפט 200 מג

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 200 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

וימפט 10 מ"ג/מ"ל ישראל - עברית - Ministry of Health

וימפט 10 מ"ג/מ"ל

cts ltd - lacosamide 10 mg / 1 ml - solution for infusion - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.vimpat solution for infusion is an alternative for patients when oral administration is temporary not feasible.